Literature DB >> 1655968

Current seroepidemiology of hepatitis A in Hong Kong.

K P Chin1, A S Lok, L S Wong, C L Lai, P C Wu.   

Abstract

The current seroepidemiology of hepatitis A in Hong Kong was examined by testing stored sera from 702 healthy subjects, collected between 1987-1989, for antibody to hepatitis A virus (anti-HAV). The overall prevalence of anti-HAV antibody was 45.6%. There were significant increases in prevalence of anti-HAV antibody with every 10-year increase in age up to age 40. The prevalence of anti-HAV antibody was 24% for subjects below age 30 and 89.2% for those above age 30 (P less than 0.0001). Socioeconomic factors did not appear to have any influence on the prevalence of anti-HAV antibody. In comparison with another study conducted in Hong Kong 10 years ago, the prevalence of anti-HAV antibody in the current study was significantly lower in every age group from 0 to 30 years. In summary, it was shown that HAV infection is no longer highly endemic in Hong Kong. In view of the changing epidemiology, postexposure prophylaxis will be necessary for young adults and children, and hepatitis A vaccine may be indicated for high risk groups when it is generally available.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655968     DOI: 10.1002/jmv.1890340312

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Partners in practice. Getting better: education and the primary health care team.

Authors:  R V Jones
Journal:  BMJ       Date:  1992-08-29

2.  Hepatitis A in urban Ireland.

Authors:  E Rajan; B O'Farrell; A G Shattock; J F Fielding
Journal:  Ir J Med Sci       Date:  1998 Oct-Dec       Impact factor: 1.568

3.  Epidemiological factors affecting hepatitis a seroprevalence in childhood in a developing country.

Authors:  Sevin Altınkaynak; Mukadder Ayşe Selimoğlu; Vildan Ertekin; Buket Kılıçaslan
Journal:  Eurasian J Med       Date:  2008-04

Review 4.  Viral hepatitis.

Authors:  G V Gregorio; G Mieli-Vergani; A P Mowat
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

5.  Clinical trial with inactivated hepatitis A vaccine and recommendations for its use.

Authors:  A J Tilzey; S J Palmer; S Barrow; K R Perry; H Tyrrell; A Safary; J E Banatvala
Journal:  BMJ       Date:  1992-05-16

6.  HAV Immunity in Iranian Medical Students.

Authors:  Seyyed Javad Hosseini Shokouh; Alireza Dadashi; Mohamad Abiri; Iraj Zohrevand; Ahad Eshraghian; Alireza Khoshdel; Behnam Heidari; Shayan Khoshkish
Journal:  Hepat Mon       Date:  2015-03-31       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.